Successful therapy of high-grade tumors of the brain is likely to require a combination of new therapeutic approaches. The major goal of the present study was to construct a plasmidbased bax gene vector (pGL1-Bax) and evaluate its expression in vitro and in vivo using athymic mice with subcutaneously growing C6 glioma. Preliminary experiments of efficacy and safety were also performed using pGL1-Bax alone and in combination with previously constructed pGL1-TNF-α, as well as with radiation. pGL1-Bax was expressed by C6 cells and was correlated with apoptosis, indicating that the construct and the bax protein were functional. Although intratumoral injections of pGL1-Bax alone, up to total doses of 450 µg, did not significantly affect tumor growth, consistently smaller tumors were obtained when pGL1-TNFα plus pGL1-Bax were injected 16-18 hr prior to tumor irradiation. Furthermore, in mice with two tumors, one treated and one untreated, progression of the untreated tumor was delayed in the animals receiving all three modalities. No prohibitive toxicities were noted, based on mouse body weights and in vitro assays of blood and spleen. Significant increases in spleen mass, total leukocyte counts, percentage of granulocytes, spontaneous blastogenesis, and CD71-expressing B cells were primarily associated with tumor presence and not treatment type. Overall, the results are promising and suggest that TNF-α/Bax gene therapy may be beneficial against highly malignant tumors of the brain. To our knowledge, this is the first report of bax gene therapy used together with radiation in an in vivo glioma model.
Introduction
According to estimates of the American Cancer Society, there will be more than 1,280,000 newly diagnosed cases of cancer in the year 2002 (1). This number of cases does not include basal and squamous cell skin cancers (>1 million), in situ breast carcinoma (54, 300) , and in situ melanoma (34, 300) . In addition to the human toll, the National Institutes of Health estimates that the overall medical costs for cancer are approximately $37 billion annually. At present, the 5-year relative survival rate for all cancers combined is 62% and more than half a million Americans die of cancer each year. The prognosis for patients with malignant brain tumor is especially poor, as might be expected with neoplasms that are highly radio-and chemoresistant. In patients with high-grade tumors of the central nervous system (CNS), radiation in combination with neurosurgery or chemotherapy has not increased survival significantly (2, 3) . Anaplastic astrocytoma and glioblastoma recur in more than 90% of patients and 5-year survival is less than 10% (4) . In addition, side effects ranging from cognitive defects to development of secondary CNS neoplasms following treatment remain a serious problem. Thus, there is a need for innovative strategies to increase both the efficacy and safety of radiotherapy for brain tumors, as well as other highly malig-nant forms of cancer. Since it is unlikely that a single therapeutic approach will provide a cure for highly malignant cancers, the search for novel combinations of modalities is underway to identify those that may offer additive or perhaps even synergistic antitumor responses with less toxicity.
In previous studies, we found that the lethal effects of radiation on cultured human colon tumor cells can be significantly augmented by tumor necrosis factor-α (TNF-α) and that the radiation-enhancing mechanism may be related to TNF-α-induced oxygen radical production by the tumor cells themselves (5) . Subsequent in vivo studies employing human recombinant TNF-α protein (given i.v.) in conjunction with radiation showed that combination treatment produced a significantly more potent antitumor effect than did radiation alone against colon, lung, and brain tumors (6) (7) (8) . The data also indicated that the mechanism of action may include not only the lethal effects of radiation and TNF-α within the tumor, but also their mutual stimulation of nonspecific effector cell populations. Although no serious side effects were noted, complete regression of established tumors did not occur and increasing the dose of TNF-α protein to potentially increase effectiveness would have also increased the risk for toxicity. The above observations led us to construct a plasmid-mediated delivery system for the TNF-α gene (pGL1-TNF-α) (9). Plasmid pGL1-TNF-α was expressed at relatively high levels by C6 glioma cells and intratumoral administration enhanced radiation efficacy against tumors growing subcutaneously (s.c.) in athymic mice (9, 10). In addition, we found that a significant radiation-enhancing effect could be achieved against established C6 tumors with a relatively low dose of pGL1-TNF-α, there is a threshold for TNF-α expression beyond which no further benefit can be gained, the efficacy of the combination treatment may be more pronounced if proton radiation is used instead of conventional γ-rays, and lymphocyte activation may play a role in the antitumor effect (11, 12) . Although the combination of pGL1-TNF-α and proton hemibrain irradiation did not significantly increase survival time for athymic rats with orthotopically implanted C6 tumors under the relatively conservative treatment conditions employed, histopathological analysis of brain sections were encouraging (13).
It has been proposed that dysregulation of apoptosis is a critical factor in tumor development and resistance to therapy (14, 15) . Thus, we postulated that a proapototic factor may produce a greater antitumor effect when used together with radiation than we had previously observed with pGL1-TNF-α (pGL1-TNF-α alone has no effect on C6 tumor growth). Furthermore, the possibility existed that the combination of both gene constructs may result in even greater radiation enhancement. Bax, a member of the bcl-2 gene family that functions to either promote or prevent apoptosis, encodes a 21 kDa protein that is proapoptotic (16) (17) (18) . Recent studies have demonstrated that loss of bax prevents apoptosis (19, 20) , whereas its overexpression facilitates apoptotic death and may increase sensitivity to apoptosis-inducing stimuli (21-25). To date, there is very little information regarding the effects of bax gene therapy in combination with radiation, although recent in vitro and in vivo data appear to be promising (26) (27) (28) . In the present study, a new plasmid-bax gene vector was constructed (pGL1-Bax) and tested both with and without pGL1-TNF-α and radiation in the C6 glioma/athymic mouse model.
Materials and Methods

Tumor Cells
The rat C6 nitrosourea-induced glioma cells, originally developed by Benda et al. (29) , were obtained from the American Type Culture Collection (ATCC, Rockville, MD). This cell line was selected because it has been extensively characterized and has many of the characteristics observed with human gliomas (30, 31). Dulbecco's minimal essential medium (DMEM; Irvine Scientific, Santa Ana, CA) supplemented with 10% bovine calf serum (Hyclone Labs, Logan, UT) and antibiotics was used for culture. The cells were incubated at 37º C in 5% CO 2 until near-confluency, harvested, washed, counted using trypan blue exclusion, and adjusted to the appropriate concentations.
pGL1-Bax, pGL1-TNF-α, and pWS4
pGL1-Bax plasmid was constructed using pWS4, a universal eukaryotic gene expression vector kindly provided by Dr. R. Dornburg (32) and plasmid pORFhBax was purchased from InvivoGen, San Diego, CA. Cloning, propagation, purification, and other procedures were the same as those used in constructing pGL1-TNF-α (9). Briefly, the cDNA encoding human bax (745 bp) was excised from pORFhBax plasmid by digestion with restriction enzymes NcoI and HpaI and cloned into BamHI-HpaI site of the plasmid pWS4, placing expression of the bax gene under the control of the cytomegalovirus (CMV) promoter and an adenovirus tripartite leader (AVtl) sequence. Proper orientation of the bax insert relative to the promoter was determined by digestion with restriction enzymes and gel electrophoresis. The correct sequence of the bax gene in pGL1-Bax was confirmed by DNA sequencing. Large amounts of the pGL1-Bax plasmid encoding human bax gene, as well as pGL1-TNF-α and parental pWS4, were prepared by Althea Technologies, Inc. (San Diego, CA) according to our specifications. The plasmid DNAs were resuspended in phosphate buffered saline (PBS) before use.
Transfection of C6 Cells
Cytofectene (Bio-Rad Laboratories, Hercules, CA) was utilized to transfect C6 cells according to the manufacturer's protocol. Briefly, the day before transfection, 7x10 5 C6 cells were plated into 60 mm plates (ISC Bioexpress, Kaysville, WI) in 5 ml of complete DMEM medium and incubated in 5% CO 2 at 37º C. On the day of transfection, the cells were at 60-80% confluency. Plasmid (4 µg/60 mm plate), with and without bax, was diluted in 200 µl of serum-free medium, mixed with 16 µl of Cytofectene, and incubated at room temperature (RT) for 20 min. The DNA/Cytofectene complex was then diluted in 1.8 ml of serum-containing medium. After aspirating the medium, the DNA/Cytofectene mixture was added to the cells which were then incubated in 5% CO 2 at 37º C overnight. On the next day, 2 ml of complete serum-containing medium was added to the cells that were then incubated for 24 h.
Immunohistochemistry for pGL1-Bax Expression by C6 Cells
C6 cells (1.5x10 5 ) were grown in 2-well Lab-Tek II Chamber slides (Nalge Nunc, Naperville, IL) and transfected as described above. The cells were washed twice with PBS, fixed with 4% paraformaldehyde in PBS at RT for 30 min and washed twice with PBS. Fixed cells were blocked with 1% bovine serum albumin in tris buffered saline (TBS) containing a 0.05% Tween-20 (TTBS) at RT for 1 h. The cells were immunolabeled with primary antibodies at RT for 3 h. Two different primary antibodies were used for labeling: polyclonal rabbit anti-human bax, which recognizes only human bax (PharMingen, San Diego, CA), was used at a 1:1000 dilution; and purified rat anti-Bax monoclonal antibody, which reacts with human and mouse bax (PharMingen), was used at 5 µg/ml. After incubation with primary antibodies, samples were washed three times in TTBS. The immunoreaction was visualized by incubating with appropriate secondary antibodies at RT for 1 h: fluorescein isothiocyanate (FITC)-conjugated AffinPure Goat Anti-Rabbit IgG, F(ab') 2 Fragment Specific (1:200, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) and Cy3-conjugated AffinPure Goat Anti-Rat IgG (1:1000, Jackson ImmunoResearch Laboratories). After several washes in TTBS, samples were counterstained with DAPI and analyzed by fluorescence microscopy.
Animals, Tumor Induction, and Tumor Volume Measurement
Athymic nude mice were purchased from Charles River Breeding Laboratories (Wilmington, MA); the animals were 5-6 weeks of age. The animals were housed 4/cage under standard vivarium conditions. A 2 to 3 week acclimatization period allowed the animals to achieve young adulthood before entry into the study. In most experiments, the mice were injected with 5 x 10 5 C6 cells in the right hind flank in a total volume of 0.1 ml/mouse. The s.c. route of tumor cell implantation was chosen so that tumor progression could be readily quantified without invasive techniques. Tumor dimensions were measured with vernier calipers and volumes were calculated: volume (mm 3 ) = (L x H x W)/2, where L, H, and W represent the length, width, and height of the tumor, respectively. All mice were observed daily for signs of toxicity and weighed periodically after treatments began. Rapid euthanasia was performed in 100% CO 2 , in compliance with the NIH Guide for the Care and Use of Laboratory Animals. This study was approved by the Institutional Animal Care and Use Committee prior to initiation.
Treatment Protocols
Phase 1 was done to determine whether administration of pGL1-Bax or pGL1-TNF-α/pGL1-Bax could modify tumor progression without the addition of radiation. Mice (n = 40, 5/group) were injected with C6 cells and assigned to groups. Beginning on day 6 after tumor cell implantation, the animals received three intratumoral injections of plasmid at varying concentrations over an 8-day period. Maximum total doses per animal ranged from 50 µg to 450 µg; total volume per injection was 37.5 µl. Tumor dimensions were measured every 2-3 days, and the animals were euthanized on day 16. The dose of plasmid selected for further experiments was the one giving the slowest tumor progression in this phase (i.e., 50 µg pGL1-TNF-α + 50 µg pGL1-Bax per injection).
In Phase 2, additional groups of mice (n = 8/group) were given three intratumoral injections of pGL1-TNF-α plus pGL1-Bax (50 µg of each/injection) and tumors in the appropriate groups were irradiated 16-18 h after each injection. Radiation at 2 gray (Gy)/fraction (1 Gy/min dose rate) was delivered using an Eldorado gamma radiation machine (Atomic Energy of Canada, Ltd., Commercial Products Division, Ottawa, Canada) containing a 60 Co source. Lipowitz metal alloy blocks shielded normal tissues and a 0.5 cm 'superflab' bolus was placed on top of each tumor to achieve full electronic equilibrium. To minimize distress and ensure immobilization, the animals were anesthesized by intraperitoneal injection of a combination of ketamine (80 mg/kg) and xylazine (5.2 mg/kg) immediately prior to tumor irradiation. Mice not receiving radiation were also anesthetized to ensure uniformity in experimental conditions. Treatments were initiated 6 days after C6 cell injection and were delivered over a period of 6 days. The selected radiation dose/fraction is typical in clinical radiotherapy regimens and has also been used in our previous studies.
Phase 3 mice (n = 56; 8 mice/group) were first injected s.c. with C6 tumor cells in the right hind flank with 5 x 10 5 cells/mouse. Six days later, the same animals were injected with one-half this amount in the contralateral flank and treatment of the tumors in the right flank began. The smaller focus of cells in the left flank simulated a "metastasized" tumor mass. Time-dose schedules were similar to phase 2, except that groups receiving 4 Gy radiation +/-pGL1-TNF-α/Bax were included. These mice were euthanized on day 16 post-C6 cell implantation.
Mice (n = 81, 9-18/group) enrolled in Phase 4 were treated similarly to those in Phase 1, except that subsets of animals from each group were euthanized at 16-18 h after each of the plasmid injections. Blood and spleens were collected for in vitro assays (described below) at the three time points of euthanasia. A group of nontumor-bearing mice were included as a source of normal control cells.
Body Weight and Relative Spleen Weight (RSW)
The mice were weighed 2-3 times each week. At the time of euthanasia, spleens were excised and weighed. The RSW was calculated as follows: RSW = [organ weight (g) x 10 4 ]/body weight (g).
Blood and Spleen Leukocyte Analysis
Aliquots (12 µl) of whole blood, collected by cardiac puncture at euthanasia, and spleen cell suspensions were analyzed using the ABC Hematology Analyzer (Heska Corp., Waukesha, WI) as previously described (13). All spleens were suspended in a total volume of 2.5 ml complete RPMI medium. The measurements reported here include white blood cell (WBC) counts and 3-part differential (lymphocytes, monocytes, and granulocytes).
Spontaneous Blastogenesis
This assay was performed as previously described (13). The test was used to quantify the basal proliferation of leukocytes in blood and spleen, based on incorporation of 3 H-thymidine ( 3 H-TdR; ICN Biochemicals, Costa Mesa, CA) into cell DNA. The counts per minute (cpm) were adjusted to 10 6 leukocytes/ml, based on the volume tested and cell numbers obtained from the Vet Analyzer (Heska Corp.).
Flow Cytometry Analysis of Lymphocytes
A FACSCalibur™ flow cytometer (Becton Dickinson, Inc., San Jose, CA) was used to quantify B and NK cell populations using fluorescence-labelled monoclonal antibodies against B220 (clone RA3-6B2) and PanNK (clone DX5). In addition, lymphocytes expressing CD71 (clone C2), B220/CD71, and PanNK/CD71 were evaluated. Lymphocytes were identified using CD45 (clone 30-F11) versus side scatter and standard, direct staining techniques were used throughout. Analysis was performed using CellQuest™ software version 3.1 (Becton Dickinson) on a total of 10,000 lymphocyte events acquired per sample.
Statistical Analysis
Quantifiable data were evaluated using one-way analysis of variance (ANOVA) and Tukey's pairwise multiple comparison test to determine differences among groups (SigmaStat™ Statistical Software version 2.03; SPCC Inc., San Rafael, CA). In Phase 4, paired comparisons were made within each time point of assay. A p value of <0.05 indicated significant differences.
Results
C6 cells transfected with pGL1-Bax or pORFhBax expressed bax protein in vitro at 48 h post-transfection, as determined by immunolabelling (Fig. 1) . Bax immunostaining was detected in the cytoplasm of the cells in a granular pattern, as is typically seen with bax. More bax-positive cells were observed in pGL1-Bax-transfected cells compared to the cells transfected with the original plasmid pORFhBax; this can be explained by the AVtl sequence enhancing the expression of the bax gene in plasmid pGL1-Bax. Nuclear fragmentation and apoptotic bodies were observed in bax-expressing C6 cells, indicating that the overexpression of bax had triggered apoptosis. There was no evidence of bax expression in mocktransfected or pWS4-transfected cells.
Phase 1 showed that intratumoral injection of pGL1-Bax alone had no effect on C6 tumor growth at total doses as high as 450 µg. pGL1-TNF-α and pGL1-Bax, administered in three intratumoral injections in combination (50 µg of each plasmid per injection) resulted in the slowest tumor progression (Fig. 2) , although statistical support was lacking. In Phase 2, the dose of pGL1-TNF-α/Bax that resulted in the smallest tumor volumes was administered 16-18 h prior to tumor irradiation with 2 Gy and each modality was again delivered three times. The data show that mean tumor volume in the pGL1-TNF-α/Bax/radiation group was 13-39%, 13-19%, 26-39%, and 9-28% smaller than the means for all 1 : Immunocytochemical analysis of human bax expression in C6 rat glioma cells. C6 cells grown on Lab-Tek II Chamber slides were mocktransfected, or transfected with pWS4 or pGL1-Bax, or pORFhBax plasmids. 48 h after transfection, cells were fixed and immunolabeled with two different anti-bax antibodies and positive signals were visualized with appropriate secondary enzyme-conjugated antibodies. Samples were counterstained with DAPI and analyzed by fluorescence microscopy (magnification x1000). Blue, cell nuclei; green and red, human bax protein expressed in the cells transfected with bax encoding plasmids.
other groups on days 10, 13, 15, and 16, respectively, after tumor cell implantation (Fig. 3) . In Phase 3, both hind legs of mice were implanted with C6 cells, but the left flank received a smaller number of the tumor cells on the day that treatments of the right flank tumor were initiated. Mean tumor volume in the treated right flank for the group receiving a combination of pGL1-TNF-α/Bax and 4 Gy radiation was 11-41% and 16-38% smaller on days 13 and 16 after C6 cell implantation, respectively, compared to all other groups (Fig. 4A ). On day 16, tumor volumes were significantly smaller in this combination group than in the control group receiving injections of PBS (P<0.05). Untreated tumors on the left flank were not detectable on day 13 (i.e., 6 days after C6 injection into left flank) in the group in which the right flank tumor received pGL1-TNF-α/Bax/4 Gy radiation, but were measurable in all of the other groups (Fig. 4B ). By day 16 (i.e. 9 days after C6 injection into left flank), the pGL1-TNF-α/Bax/4 Gy radiation and 4 Gy radiation groups had the smallest mean tumor volumes. No further follow up could be done on these mice, because tumor size in the right flank had reached the maximum allowed limit.
Phase 4 was performed to determine the extent to which leukocyte populations might be affected by the treatments and to identify potential toxicities. Mice were euthanized for assay at 16-18 hr after 1, 2, and 3 intratumoral injections of both plasmid constructs on days 7, 10, and 14 after C6 cell implantation, respectively. There were no significant differences in mean tumor volumes among groups at the first and third times of assay, with the ranges being: 73.7 +/-12.1 mm 3 to 115 +/-16 mm 3 (time 1) and 1,138 +/-263 mm 3 to 1,915 +/-255 mm 3 (time 3). At the second time point of assay, however, the mean tumor volume of 217 +/-32 mm 3 for the pGL1-TNF-α/Bax group was significantly lower than the 459 +/-67 mm 3 obtained for the PBS control group (P<0.05). Average body masses were generally similar among groups, ranging from 25.1 +/-0.6 g to 30.5 +/-1.2 g. On the day after the third injection all mice with tumor had the highest leukocyte numbers; significant elevations were noted in the blood from the PBS control group (Table I ) and in the spleens from all three tumor-bearing groups (Table II) compared to animals with no tumor (P<0.05 or less). At this same time point, spleen mass and leukocyte proliferation were increased, whereas blood leukocyte proliferation was somewhat depressed, especially in the PBS control group (P<0.05 or less) (Table III) . All tumorbearing groups had a significantly lower proportion of PanNK + splenocytes after the third injection compared to the control group without tumor (P<0.001); a transient increase in the percentage of B cells was noted in blood from the pWS4 and pGL1-TNF-α/Bax groups after the first injection (P<0.05) (Table IV) . As shown in Table V , the proportion of lymphocytes expressing the CD71 marker was decreased at time 1 in the blood from pGL1-TNF-α/Bax-injected mice (P<0.05), but this depression was not sustained. By the time of the third injection, a high percentage of CD71-expressing cells were observed in the spleens from all three tumor-bearing groups and the great majority of these cells also expressed B220 (P<0.05 or less); in the blood, an increase was noted only in the PBS control group. There were no significant differences in expression of PanNK/CD71.
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Discussion
A major goal of this study was to construct a vector delivery system for the human bax gene and test its biological activity both in vitro and in vivo. The parental plasmid was the same as was used in the development of pGL1-TNF-α so that comparisons of efficacy could be made. pGL1-Bax was constructed successfully and human bax production was demonstrated in C6 cells. Presence of morphologically typical apoptotic bodies in bax-positive cells confirmed that the expressed protein was functional. In other studies, bax overexpression in breast and ovarian carcinomas has dramatically increased cell sensitivity to chemotherapeutic agents (21, 24) . It has also been shown that C6 glioma cells transfected with the murine bax gene have a decreased growth rate compared to untransfected C6 (33) . In this latter study, treatment with cytosine arabinoside resulted in more cells undergoing apoptosis in the cell line overexpressing bax than in the vector-only controls. A study of medulloblastoma (radiosensitive) and glioblastoma (radioresistant) cells lines, all of which expressed wild-type p53, concluded that the lack of radiation-induced apoptosis in the glioblastoma lines was due to failure of p53 to induce bax. The conclusion was supported by findings that forced expression of bax in the glioblastomas was sufficient to activate apoptosis, whereas inhibition of bax in the medulloblastomas resulted in a loss of radiation-induced apoptosis. The investigators in this latter study suggested that the inability of p53 to induce bax expression may be a critical factor in determining therapeutic responsiveness to radiation in high-grade tumors of the brain. Other studies have revealed numerous abnormalities in gliomas, including p53 mutations, ras overexpression, and epidermal growth factor receptor amplification (34) (35) (36) . Gene therapy strategies for these, as well as other tumor types, have included overex-pression of p53, myc, p21 WAFI/CIP1 , viral thymidine kinase, TNF-α, and interleukin-1β-converting enzyme (37-41). In most cases, these approaches have slowed, but not eliminated, tumor growth.
Based on results from Phase 1 of the present study, pGL1-Bax alone had no significant effect on C6 tumor growth. However, pGL1-TNF-α and pGL1-Bax when used in combination, at a total dose of 150 µg each, resulted in the slowest tumor progression. In addition, a dose threshold was reached above which no further benefit was achieved. These findings are similar to our previous observations with pGL1-TNF-α (11). Furthermore, treatment with pGL1-TNF-α plus pGL1-Bax together with radiation (Phase 2) resulted in consistently smaller tumors, although statistically significant tumor growth inhibition was not achieved compared to radiation alone. The lack of more dramatic radiation-enhancing effects may be due to use of the human versions of the TNF-α and bax genes. Future investigations using human brain tumor models should reveal whether similar, or perhaps greater, tumor inhibition is possible with these human gene constructs. In a previous study, we found that intratumoral administration of a pcDNA plasmid containing murine bax resulted in significantly slower C6 tumor growth compared to PBS-injected controls (p<0.01). Tumor volumes in the mice treated with pcDNA-bax were -4.34 69.0 +/-1.1 25.1 +/-0.9 5.9 +/-0.2 e pGL1-TNF-α + pGL1-Bax approximately 45% smaller than in the control group by day 12 (42). Others have reported that bax expression can augment the effect of radiation in vitro. For example, the introduction of a plasmid containing the human bax gene into MCF-7 human breast cancer cells increased their sensitivity to ionizing radiation compared to the parental . Transfection of cultured human tumor cells with p4NFB-BAX significantly reduced the number of cells surviving 2 Gy irradiation (28). In vivo studies combining bax gene therapy and radiation are virtually nonexistent. One recent report demonstrated that augmentation of the effects of radiotherapy against human ovarian tumors xenotransplanted in mice was possible using a recombinant adenovirus encoding bax (26).
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In Phase 4, C6 tumor cells were implanted in two separate sites within the same animals. Our previous studies using pGL1-TNF-α in concert with radiation indicated that at least some of the increased antitumor effect of combination treatment may be due to upregulation of leukocyte activity (8-13). Thus, we postulated that delay in progression of a second, untreated tumor mass in the same animal might be possible. In the present study, a small focus of C6 cells was implanted into the contralateral flank at the time that treatment of the primary tumor was initiated. site represented a small focus of cells that had extended beyond the immediate field of treatment or that metastasized to a site distant from the primary tumor mass. The delayed growth of the untreated tumors in mice receiving pGL1-TNFα, pGL1-Bax, and radiation suggests that activation of circulating effector cell populations may be involved. However, in vitro assays of blood and spleen leukocytes tended to reflect more the presence and size of the tumor load, rather than the effects of treatment. Nonetheless, the data also showed a significant increase in the granulocytes. The neutrophils, being the most abundant granulocytes in circulation, are well known to be capable of tumor cell destruction (43, 44) .
Conclusions
Gene therapy in combination with radiation is a relatively new approach for cancer treatment. It has the potential to radiosensitize malignant cells selectively and to enhance immunological responsiveness. The present study is the first, to our knowledge, to evaluate bax gene therapy in combination with radiation against glioma in an in vivo model. Overall, the results indicate that this approach may be beneficial. However, more work is obviously needed to determine whether the regimen is feasible in patients with high-grade tumors of the CNS and to more specifically identify the possible mechanisms of action.
